Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunoadsorption in pemphigus.

Rüdiger Eming1, Michael Hertl

  • 1Department of Dermatology and Allergology, University Hospital, Philipps University, Marburg, Germany. eming@med.uni-marburg.de

Autoimmunity
|November 15, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.

Acta dermato-venereologica·2026
Same author

A case series of immune checkpoint inhibitor-induced bullous pemphigoid successfully treated with dupilumab and evidence for the BP180 midportion epitope as a preferential autoantigenic target.

Frontiers in medicine·2026
Same author

International development of Investigator Global Assessment scores for pemphigus.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Wnt-associated DKK3 in keratinocytes mediates radiation-induced hyperplasia, dermatitis and skin fibrosis.

Signal transduction and targeted therapy·2026
Same author

Digital health applications, telemedicine and large language models in dermatology: results of a Germany-wide survey.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

Structured Symptom Assessment in Dermato-Oncology Patients-A Prospective Observational Study of the Usability of a Symptom Questionnaire.

Cancers·2025
Same journal

CCDC77 and SLC45A3 mediate the genetic mechanism of Hashimoto's thyroiditis through IL-6.

Autoimmunity·2026
Same journal

Multi-cohort transcriptomic analysis with machine learning identifies interferon-related candidate genes in systemic lupus erythematosus.

Autoimmunity·2026
Same journal

IgA Vasculitis with necrotizing arteritis: a multicenter retrospective study from the French Vasculitis Study Group and systematic review of the literature.

Autoimmunity·2026
Same journal

Global research trends in ferroptosis in autoimmune diseases: a bibliometric and visual analysis (2018-2025).

Autoimmunity·2026
Same journal

Monocyte exhaustion associated with systemic lupus erythematosus.

Autoimmunity·2026
Same journal

Statement of Retraction: Long non-coding RNA LINC00265 promotes proliferation, apoptosis, and inflammation of chondrocytes in osteoarthritis by sponging miR-101-3p.

Autoimmunity·2026
See all related articles

Extracorporeal immunoadsorption (IA) effectively removes pathogenic autoantibodies in pemphigus, a severe autoimmune blistering disease. This treatment leads to significant clinical improvement and is a safe, well-tolerated adjuvant therapy.

Area of Science:

  • Immunology
  • Dermatology
  • Medical Technology

Background:

  • Pemphigus is a severe autoimmune blistering disease.
  • Pathogenic autoantibodies target desmosomal and non-desmosomal antigens on keratinocytes.
  • Autoantibodies play a key role in pemphigus pathogenesis.

Purpose of the Study:

  • To evaluate the efficacy of extracorporeal immunoadsorption (IA) in treating severe pemphigus.
  • To assess the impact of IA on autoantibody levels and clinical outcomes.
  • To determine the safety and tolerability of IA as an adjuvant therapy for pemphigus.

Main Methods:

  • Extracorporeal immunoadsorption (IA) targeting pathogenic autoantibodies and circulating immune complexes (CIC).
  • Treatment protocols involved cycles of IA followed by maintenance therapy.

Related Experiment Videos

  • IA was used as an adjuvant treatment combined with systemic immunosuppressive medication.

    • Main Results:

    • IA demonstrated a rapid and significant decline in desmoglein (Dsg)-reactive autoantibodies.
    • A dramatic decrease in autoantibody levels correlated with clinical remission of mucocutaneous blisters and erosions.
    • IA was found to be generally safe and well-tolerated in patients with severe pemphigus.

    Conclusions:

    • Extracorporeal immunoadsorption is an effective adjuvant therapy for severe pemphigus.
    • IA successfully reduces pathogenic autoantibodies, leading to clinical improvement.
    • The treatment is safe and well-tolerated, offering a valuable option for pemphigus management.